IN2015DN00598A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN00598A IN2015DN00598A IN598DEN2015A IN2015DN00598A IN 2015DN00598 A IN2015DN00598 A IN 2015DN00598A IN 598DEN2015 A IN598DEN2015 A IN 598DEN2015A IN 2015DN00598 A IN2015DN00598 A IN 2015DN00598A
- Authority
- IN
- India
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- acceptable salt
- embodiment provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261677307P | 2012-07-30 | 2012-07-30 | |
| PCT/US2013/052721 WO2014022390A1 (en) | 2012-07-30 | 2013-07-30 | Deuterated ibrutinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00598A true IN2015DN00598A (instruction) | 2015-06-26 |
Family
ID=48917743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN598DEN2015 IN2015DN00598A (instruction) | 2012-07-30 | 2013-07-30 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9422295B2 (instruction) |
| EP (1) | EP2882751B1 (instruction) |
| JP (1) | JP6261580B2 (instruction) |
| KR (1) | KR20150038486A (instruction) |
| CN (1) | CN104507946A (instruction) |
| AU (1) | AU2013296627C9 (instruction) |
| BR (1) | BR112015001839A2 (instruction) |
| CA (1) | CA2879400A1 (instruction) |
| EA (1) | EA201590296A1 (instruction) |
| ES (1) | ES2682043T3 (instruction) |
| IN (1) | IN2015DN00598A (instruction) |
| MX (1) | MX2015001246A (instruction) |
| WO (1) | WO2014022390A1 (instruction) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6261580B2 (ja) | 2012-07-30 | 2018-01-17 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化イブルチニブ |
| CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| CN103965201A (zh) * | 2014-04-30 | 2014-08-06 | 淮海工学院 | 一种合成依鲁替尼中间体4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶的方法 |
| CN104945404B (zh) * | 2014-06-25 | 2018-09-14 | 广东东阳光药业有限公司 | 一种n-丙烯羰基哌啶衍生物的制备方法 |
| MA41350A (fr) * | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
| EP3257855B1 (en) * | 2015-02-12 | 2020-04-22 | Shanghai Dude Medical Science and Technology Co., Ltd. | Method for preparing ibrutinib |
| WO2016132383A1 (en) * | 2015-02-18 | 2016-08-25 | Mylan Laboratories Limited | Process for the preparation of ibrutinib |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| WO2016151438A1 (en) * | 2015-03-20 | 2016-09-29 | Sun Pharmaceutical Industries Limited | A process for the preparation of ibrutinib |
| BR112018072339A2 (pt) * | 2016-05-04 | 2019-02-19 | Concert Pharmaceuticals, Inc. | tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados |
| WO2018187187A1 (en) * | 2017-04-04 | 2018-10-11 | Combiphos Catalysts, Inc. | Deuterated (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide |
| TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
| CN109988175A (zh) * | 2019-04-28 | 2019-07-09 | 梯尔希（南京）药物研发有限公司 | 一种依鲁替尼-d5的制备方法 |
| CN112876484B (zh) * | 2020-08-31 | 2022-06-28 | 绍兴舜邦医药科技有限公司 | 一种氘代依鲁替尼的制备方法 |
| CN114105990A (zh) * | 2020-08-31 | 2022-03-01 | 北京四环制药有限公司 | 一种伊布替尼的合成方法 |
| CN112125913B (zh) * | 2020-10-29 | 2024-07-19 | 瑞阳制药股份有限公司 | 高纯度伊布替尼的合成方法 |
| WO2023284765A1 (zh) * | 2021-07-16 | 2023-01-19 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑类化合物及包含该化合物的组合物及其用途 |
| WO2024109676A1 (zh) * | 2022-11-21 | 2024-05-30 | 天津征程医药科技有限公司 | 具有btk抑制作用的吡唑并嘧啶衍生物 |
| CN118063429B (zh) * | 2022-11-23 | 2025-02-25 | 天津瑞程健达医药科技有限公司 | 作为btk抑制剂的吡啶酰胺类化合物 |
| CN118307541A (zh) * | 2023-01-09 | 2024-07-09 | 天津济坤医药科技有限公司 | 氘代吡唑并嘧啶衍生物及其制备方法和药物组合物、结合物及应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE372966T1 (de) | 1994-03-25 | 2007-09-15 | Isotechnika Inc | Verbesserung der effektivität von arzneimitteln duren deuterierung |
| US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| ES2193921T3 (es) | 1999-12-03 | 2003-11-16 | Pfizer Prod Inc | Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos. |
| DE10155018A1 (de) * | 2001-11-07 | 2003-07-10 | Berolina Drug Dev Ab Svedala | Deuterierte Pyrazolopyrimidinone sowie diese Verbindungen enthaltende Arzneimittel |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| JP2006219373A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
| WO2007041630A1 (en) | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
| MX2009002398A (es) | 2006-09-05 | 2009-03-16 | Schering Corp | Combinaciones farmaceuticas para manejo de lipidos y en el tratamiento de aterosclerosis y estatosis hepatica. |
| DK2526933T3 (en) * | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| WO2013118150A1 (en) | 2012-02-08 | 2013-08-15 | Council Of Scientific & Industrial Research | "electronically conducting carbon and carbon-based material by pyrolysis of dead leaves and other similar natural waste" |
| JP6261580B2 (ja) * | 2012-07-30 | 2018-01-17 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化イブルチニブ |
-
2013
- 2013-07-30 JP JP2015525512A patent/JP6261580B2/ja not_active Expired - Fee Related
- 2013-07-30 IN IN598DEN2015 patent/IN2015DN00598A/en unknown
- 2013-07-30 MX MX2015001246A patent/MX2015001246A/es unknown
- 2013-07-30 AU AU2013296627A patent/AU2013296627C9/en not_active Ceased
- 2013-07-30 ES ES13745554.9T patent/ES2682043T3/es active Active
- 2013-07-30 CA CA2879400A patent/CA2879400A1/en not_active Abandoned
- 2013-07-30 EP EP13745554.9A patent/EP2882751B1/en active Active
- 2013-07-30 KR KR20157005220A patent/KR20150038486A/ko not_active Withdrawn
- 2013-07-30 BR BR112015001839A patent/BR112015001839A2/pt not_active IP Right Cessation
- 2013-07-30 US US14/418,831 patent/US9422295B2/en active Active
- 2013-07-30 WO PCT/US2013/052721 patent/WO2014022390A1/en active Application Filing
- 2013-07-30 CN CN201380040337.9A patent/CN104507946A/zh active Pending
- 2013-07-30 EA EA201590296A patent/EA201590296A1/ru unknown
-
2016
- 2016-07-27 US US15/220,642 patent/US9777009B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2682043T3 (es) | 2018-09-18 |
| US9777009B2 (en) | 2017-10-03 |
| CA2879400A1 (en) | 2014-02-06 |
| EA201590296A1 (ru) | 2015-07-30 |
| US9422295B2 (en) | 2016-08-23 |
| JP2015528020A (ja) | 2015-09-24 |
| AU2013296627C9 (en) | 2018-03-22 |
| EP2882751A1 (en) | 2015-06-17 |
| WO2014022390A1 (en) | 2014-02-06 |
| AU2013296627A1 (en) | 2015-02-05 |
| JP6261580B2 (ja) | 2018-01-17 |
| KR20150038486A (ko) | 2015-04-08 |
| US20170015670A1 (en) | 2017-01-19 |
| CN104507946A (zh) | 2015-04-08 |
| AU2013296627B2 (en) | 2016-07-14 |
| MX2015001246A (es) | 2015-04-10 |
| US20150210699A1 (en) | 2015-07-30 |
| EP2882751B1 (en) | 2018-06-27 |
| BR112015001839A2 (pt) | 2017-07-04 |
| AU2013296627C1 (en) | 2016-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00598A (instruction) | ||
| MX361499B (es) | Baricitinib deuterado. | |
| PH12015502031A1 (en) | Tetrahydropyrrolothiazine compounds | |
| PH12014501653A1 (en) | Metalloenzyme inhibitor compounds | |
| IN2015DN00960A (instruction) | ||
| MY163187A (en) | Novel imidazo-oxazine compound or salt thereof | |
| EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
| CR20140306A (es) | Fluormetil -5,6-dihidro-4h-[1,3] oxazinas | |
| MX370649B (es) | Proceso para la preparacion de teneligliptina. | |
| MX2015008829A (es) | Momelotinib deuterado. | |
| JO3318B1 (ar) | مثبطات bace | |
| IN2014DN07996A (instruction) | ||
| CR20140495A (es) | 5-amino[1,4]thiazines como inhibidores de bace1 | |
| MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
| IN2014DN10669A (instruction) | ||
| PH12016501183A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| AU2013347232A8 (en) | 3-Aminocyclopentane carboxamide derivatives | |
| PH12016501184A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| TN2016000181A1 (en) | Novel compound for treatment of severe hypoglycemia. | |
| MX2015012610A (es) | Pacritinib deuterizado. | |
| EA201690593A1 (ru) | Новые соединения мочевины | |
| IN2013CH05395A (instruction) | ||
| MX2015001134A (es) | Compuestos terapeuticos. | |
| UA72478U (ru) | Применение полентара как средства фригопротекторного действия |